US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
MXPA03003612A
(es)
|
2000-10-23 |
2003-06-19 |
Smithkline Beecham Corp |
Compuestos novedosos.
|
ATE305303T1
(de)
*
|
2001-02-12 |
2005-10-15 |
Hoffmann La Roche |
6-substituierte pyridopyrimidine
|
JP4166991B2
(ja)
|
2001-02-26 |
2008-10-15 |
田辺三菱製薬株式会社 |
ピリドピリミジンまたはナフチリジン誘導体
|
AU2002324450A1
(en)
*
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel pyridopyrimidines and uses thereof
|
US20030100572A1
(en)
*
|
2001-06-21 |
2003-05-29 |
Ariad Pharmaceuticals,Inc. |
Novel pyridopyrimidones and uses thereof
|
SI1470124T1
(sl)
|
2002-01-22 |
2006-04-30 |
Warner Lambert Co |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
|
AU2003225072A1
(en)
|
2002-04-19 |
2003-11-03 |
Smithkline Beecham Corporation |
Novel compounds
|
DE60313339T2
(de)
|
2002-07-31 |
2008-01-03 |
Critical Outcome Technologies, Inc. |
Protein tyrosin kinase inhibitoren
|
US7629347B2
(en)
|
2002-10-09 |
2009-12-08 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
MXPA05007503A
(es)
*
|
2003-01-17 |
2005-09-21 |
Warner Lambert Co |
Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
CA2536954C
(en)
|
2003-08-29 |
2012-11-27 |
Exelixis, Inc. |
C-kit modulators and methods of use
|
EP1685131B1
(en)
|
2003-11-13 |
2007-03-07 |
F. Hoffmann-La Roche AG |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004033670A1
(de)
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
FR2873118B1
(fr)
|
2004-07-15 |
2007-11-23 |
Sanofi Synthelabo |
Derives de pyrido-pyrimidine, leur application en therapeutique
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
EP1630163A1
(de)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
CA2575804A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Boehringer Ingelheim International Gmbh |
Pteridinones used as plk (polo like kinase) inhibitors
|
DE102004058337A1
(de)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
JP2008527007A
(ja)
|
2005-01-14 |
2008-07-24 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
Raf−キナーゼ阻害活性を有するシンナミドおよびヒドロシンナミド誘導体
|
JP2008535822A
(ja)
|
2005-03-25 |
2008-09-04 |
グラクソ グループ リミテッド |
新規化合物
|
TW200724142A
(en)
|
2005-03-25 |
2007-07-01 |
Glaxo Group Ltd |
Novel compounds
|
TWI389690B
(zh)
|
2005-03-25 |
2013-03-21 |
Glaxo Group Ltd |
新穎化合物(一)
|
KR20080002865A
(ko)
|
2005-03-25 |
2008-01-04 |
글락소 그룹 리미티드 |
피리도[2,3-d]피리미딘-7-온 및3,4-디히드로피리미도[4,5-d]피리미딘-2(1h)-온유도체의 제조 방법
|
US7737155B2
(en)
*
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
FR2887882B1
(fr)
|
2005-07-01 |
2007-09-07 |
Sanofi Aventis Sa |
Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
|
US7642270B2
(en)
|
2005-09-14 |
2010-01-05 |
Janssen Pharmaceutica N.V. |
5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
|
TW200800983A
(en)
|
2005-09-14 |
2008-01-01 |
Janssen Pharmaceutica Nv |
5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
|
EA016945B1
(ru)
*
|
2005-10-07 |
2012-08-30 |
Экселиксис, Инк. |
ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
|
US8247408B2
(en)
*
|
2005-10-07 |
2012-08-21 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
|
FR2896246B1
(fr)
|
2006-01-13 |
2008-08-15 |
Sanofi Aventis Sa |
Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
SI2074122T1
(sl)
|
2006-09-15 |
2011-10-28 |
Pfizer Prod Inc |
Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3
|
JP2010506902A
(ja)
*
|
2006-10-16 |
2010-03-04 |
ジーピーシー・バイオテック・インコーポレーテッド |
ピリド[2,3−d]ピリミジン類およびキナーゼ阻害剤としてのそれらの使用
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
WO2008055013A2
(en)
*
|
2006-10-31 |
2008-05-08 |
Janssen Pharmaceutica N.V. |
5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
|
FR2910813B1
(fr)
|
2006-12-28 |
2009-02-06 |
Sanofi Aventis Sa |
Nouvelle utilisation therapeutique pour le traitement des leucemies
|
AU2008237507B2
(en)
*
|
2007-04-03 |
2014-03-20 |
Array Biopharma Inc. |
Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
|
AU2008262837B2
(en)
*
|
2007-06-15 |
2013-05-23 |
Msd K.K. |
Bicycloaniline derivative
|
EP2185559A1
(en)
|
2007-08-03 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Crystalline form of a dihydropteridione derivative
|
AU2008343932B2
(en)
|
2007-12-19 |
2013-08-15 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
WO2009079797A1
(en)
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
EP2100894A1
(en)
*
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
MX2010010975A
(es)
|
2008-04-07 |
2010-11-01 |
Amgen Inc |
Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
CA2999321A1
(en)
|
2008-07-17 |
2010-01-21 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
PA8843901A1
(es)
|
2008-09-30 |
2010-05-26 |
|
INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
JP2013507395A
(ja)
*
|
2009-10-09 |
2013-03-04 |
アフラクシス・インコーポレイテッド |
Cns障害治療用の8−エチル−6−(アリール)ピリド[2,3−d]ピリミジン−7(8h)−オン
|
US8889696B2
(en)
|
2009-12-18 |
2014-11-18 |
Temple University—Of the Commonwealth System of Higher Education |
Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
|
WO2011100319A1
(en)
|
2010-02-09 |
2011-08-18 |
Exelixis, Inc. |
Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
|
US8987272B2
(en)
|
2010-04-01 |
2015-03-24 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of HIV
|
US8987267B2
(en)
|
2010-08-05 |
2015-03-24 |
Temple University—Of the Commonwealth System of Higher Education |
2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
JP6000273B2
(ja)
|
2010-11-29 |
2016-09-28 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
大環状キナーゼ阻害剤
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
KR101606250B1
(ko)
|
2011-03-23 |
2016-03-24 |
암젠 인크 |
Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
KR102027598B1
(ko)
*
|
2011-05-17 |
2019-10-01 |
프린시피아 바이오파마, 인코퍼레이티드 |
타이로신 키나아제 저해제
|
MX2014010176A
(es)
*
|
2012-02-23 |
2014-11-10 |
Abbvie Inc |
Inhibidores de cinasas de piridopirimidinona.
|
SI2958916T1
(sl)
*
|
2013-02-21 |
2018-11-30 |
Pfizer Inc. |
Trdne oblike selektivnih zaviralcev CDK4/6
|
EP3024464A1
(en)
|
2013-07-26 |
2016-06-01 |
Boehringer Ingelheim International GmbH |
Treatment of myelodysplastic syndrome
|
CA2954189A1
(en)
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
TWI646094B
(zh)
*
|
2016-06-01 |
2019-01-01 |
大陸商貝達藥業股份有限公司 |
Crystal form of inhibitory protein kinase active compound and application thereof
|
TN2019000039A1
(en)
|
2016-08-15 |
2020-07-15 |
Pfizer |
Pyridopyrimdinone cdk2/4/6 inhibitors
|
WO2018160076A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Auckland Uniservices Limited |
Fgfr kinase inhibitors and pharmaceutical uses
|
EP3752491A4
(en)
|
2018-02-15 |
2021-12-01 |
Nuvation Bio Inc. |
HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS
|
TW202035406A
(zh)
*
|
2018-12-07 |
2020-10-01 |
大陸商杭州英創醫藥科技有限公司 |
作為cdk-hdac雙通路抑制劑的雜環化合物
|
CN112759589B
(zh)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
嘧啶并吡啶酮类化合物及其应用
|
US11697648B2
(en)
|
2019-11-26 |
2023-07-11 |
Theravance Biopharma R&D Ip, Llc |
Fused pyrimidine pyridinone compounds as JAK inhibitors
|
WO2022188755A1
(zh)
*
|
2021-03-08 |
2022-09-15 |
暨南大学 |
吡啶并嘧啶类化合物及其应用
|
WO2024056091A1
(zh)
*
|
2022-09-16 |
2024-03-21 |
华东师范大学 |
作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
|
WO2024099403A1
(zh)
*
|
2022-11-10 |
2024-05-16 |
北京普祺医药科技股份有限公司 |
一种具有软药性质的硫醚类化合物、药物组合物及其用途
|
WO2024107730A1
(en)
*
|
2022-11-14 |
2024-05-23 |
Onconova Therapeutics, Inc. |
Methods and compositions for treating cancer
|